Paladin Labs announces approval of Wakix (pitolisant) in Canada

Paladin Labs

9 June 2021 - Paladin Labs today announced Health Canada's approval of Wakix (pitolisant) for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.

Paladin plans to work collaboratively with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et en services sociaux (INESSS) to ensure patients have access to Wakix as soon as possible.

Read Paladin Labs press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada